Navigation Links
Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
Date:1/15/2009

New hires bring over 25 years of life sciences marketing experience to Cyntellect

SAN DIEGO, Jan. 15 /PRNewswire/ -- Cyntellect, a privately-held life sciences company leading the development and commercialization of live cell analysis and manipulation systems, announced today that it has appointed Dr. Stella Redpath as Director of Product Marketing for the company's Cell Health product line and Dr. Baggi Somasundaram as Product Marketing Manager for the company's cell purification product line.

"The extensive marketing and product management experience in the life sciences research market of Drs. Redpath and Somasundaram, particularly in the cellular bioassay and analysis markets, will accelerate the commercialization of Cyntellect's products for applications in biopharmaceutical cell line development, cell line development for drug discovery and research, and key applications utilizing stem cells and primary cells and for Cell Health applications," said David Burns, Cyntellect's VP Sales & Marketing and Chief Operating Officer. "We are very pleased to add the caliber and extensive experience of both Stella and Baggi to the Cyntellect commercial team."

Prior to joining Cyntellect, Dr. Redpath was a senior marketing manager at Millipore Corporation, where she led the predictive toxicology and high content analysis programs. She has also held business and sales positions at GE Healthcare, in the Advanced Systems Business Unit, and at Ciphergen Biosystems where she was Instrumentation Product Manager. Dr. Redpath was a Research Fellow in the Department of Immunology at the Scripps Research Institute (TSRI), and earned a Ph.D in Molecular Immunology in 1996 from the University of Cambridge, UK.

Prior to joining Cyntellect, Dr. Somasundaram was a Product Manager at BD Biosciences, where he managed the high content and confocal imaging platforms. He has also held business manager and sales positions at Atto Biosciences, and at PerkinElmer where he was the Applications Manager Live Cell Confocal Imaging Platform. Dr. Somasundaram was a Senior Research Fellow in the Department of Physiology, University of Cambridge, UK and at the Babraham Institute, Cambridge, and earned a Ph.D from the University of Wales, UK.

About Cyntellect

Cyntellect, Inc. is a life sciences company committed to revolutionizing the use of living cells in life science research and cellular therapy. The Company combines expertise in high-speed cell imaging and laser-based manipulation to develop products that enable novel cell imaging, purification, and transfection capabilities to enhance the productivity of laboratory research, recombinant protein production, high-content cellular assays, functional genomics and proteomics, and cell purification, including processing of cells for therapeutic transplantation. For additional information please visit the Company's web site at www.cyntellect.com.


'/>"/>
SOURCE Cyntellect, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cyntellect to Collaborate With the Burnham Institute for Medical Research
2. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
3. University of Florida and Cyntellect Collaborate to Unlock Mysteries of Cancer Stem Cells
4. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
5. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
6. Codexis Appoints Singapore Laboratories Managing Director
7. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
11. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
Breaking Biology News(10 mins):